ArticleOncotarget2015
Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Association between rs1862513 and rs3745367 Genetic Polymorphisms of Resistin and Risk of Cancer: A Meta-AnalysisAsian Pacific journal of cancer prevention : APJCP · 2018Pooled it
- Racial and ethnic disparities in T helper 2-mediated inflammatory skin disorders.Skin health and disease · 2026Review
- Remodeling the Immune Landscape: How Obesity-Induced SASPs Create a Pro-Tumorigenic Niche.Current obesity reports · 2026Review
- Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis.NPJ breast cancer · 2026Article
- Targeting Matrix Stiffness and Mechanotransduction in Breast Cancer: Implications for Emerging Therapies.International journal of molecular sciences · 2026Review
- The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis.Journal of cancer research and clinical oncology · 2025Review
- The Role of Obesity in the Regulation of Immunosuppressive Cell Infiltration and Immunosurveillance in Cancers.Diseases (Basel, Switzerland) · 2025Review
- A Society-to-Cells approach to evaluating multilevel and interrelated drivers of breast cancer disparities in Black women.NPJ breast cancer · 2025Review
- Targeting racial disparities in breast cancer: mechanistic insights and therapeutic potential of African medicinal plants.Medical oncology (Northwood, London, England) · 2025Review
- The role of RETN in stomach adenocarcinoma (STAD): insights from pan-cancer analysis of RNA-seq data based on the TCGA database.Discover oncology · 2025Article
- Decoding Resistin Gene Polymorphisms: Implications for Lung Cancer Risk and Clinical Outcomes of Platinum-Based Chemotherapy.Biomedicines · 2025Article
- Impact of Structural Racism and Social Determinants of Health on Disparities in Breast Cancer Mortality.Cancer research · 2024Review
- Baseline sLAG-3 levels in Caucasian and African-American breast cancer patients.Breast cancer research and treatment · 2024Article
- Racial Disparities in Plasma Cytokine and Microbiome Profiles.Microorganisms · 2024Article
- Adipo-oncology: adipocyte-derived factors govern engraftment, survival, and progression of metastatic cancers.Cell communication and signaling : CCS · 2024Review
- Exploring the multifaceted role of obesity in breast cancer progression.Frontiers in cell and developmental biology · 2024Review
- Diabetes Mellitus and Thyroid Cancers: Risky Correlation, Underlying Mechanisms and Clinical Prevention.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes.Cancer reports (Hoboken, N.J.) · 2023Review
- Serum resistin and the risk for hepatocellular carcinoma in diabetic patients.World journal of gastroenterology · 2023Review
- Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer.NPJ breast cancer · 2023Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
African-American (AA) women with breast cancer (BC) are diagnosed with more aggressive disease, have higher risk of recurrence and poorer prognosis as compared to Caucasian American (CA) women. Therefore, it is imperative to define the factors associated with such disparities to reduce the unequal burden of cancer. Emerging data suggest that inherent differences exist in the tumor microenvironment of AA and CA BC patients, however, its molecular bases and functional impact have remained poorly understood. Here, we conducted cytokine profiling in serum samples from AA and CA BC patients and identified resistin and IL-6 to be the most differentially-expressed cytokines with relative greater expression in AA patients. Resistin and IL-6 exhibited positive correlation in serum levels and treatment of BC cells with resistin led to enhanced production of IL-6. Moreover, resistin also enhanced the expression and phosphorylation of STAT3, and treatment of BC cells with IL-6-neutralizing antibody prior to resistin stimulation abolished STAT3 phosphorylation. In addition, resistin promoted growth and aggressiveness of BC cells, and these effects were mediated through STAT3 activation. Together, these findings suggest a crucial role of resistin, IL-6 and STAT3 in BC racial disparity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.